Last reviewed · How we verify
AIR645
AIR645 is an inhaled biologic that targets airway inflammation through a mechanism involving immune modulation in the respiratory tract.
AIR645 is an inhaled biologic that targets airway inflammation through a mechanism involving immune modulation in the respiratory tract. Used for Inflammatory airway disease (specific indication under investigation in Phase 2).
At a glance
| Generic name | AIR645 |
|---|---|
| Sponsor | Altair Therapeutics, Inc. |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 2 |
Mechanism of action
AIR645 is designed as a locally-acting therapeutic delivered via inhalation to treat inflammatory airway diseases. The drug's specific molecular mechanism and target remain proprietary to Altair Therapeutics, but development has focused on respiratory indications where local lung delivery may provide therapeutic benefit with reduced systemic exposure.
Approved indications
- Inflammatory airway disease (specific indication under investigation in Phase 2)
Common side effects
Key clinical trials
- Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma (PHASE2)
- A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AIR645 CI brief — competitive landscape report
- AIR645 updates RSS · CI watch RSS
- Altair Therapeutics, Inc. portfolio CI